Newmont (TSX:NGT,NYSE:NEM,ASX:NEM) is preparing to withdraw from the TSX, the latest in a string of moves to streamline operations and rein in costs following its US$15 billion takeover of Newcrest…
-
-
Barrick Mining (TSX:ABX,NYSE:B) has agreed to sell its Hemlo gold mine in Ontario, Canada, for up to US$1.09 billion, continuing the company’s shift away from non-core assets. The company announced…
-
(TheNewswire) Vancouver, British Columbia TheNewswire – September 15th, 2025 Prismo Metals Inc. (the ‘ Company ‘ ) (CSE: PRIZ,OTC:PMOMF) (OTCQB: PMOMF) is pleased to report that its exploration team has…
-
Investing
Kobo Resources Closes Second and Final Tranche of the Upsized Non-Brokered Private Placement for Gross Proceeds of Over $3.96 Million
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. Kobo…
-
Investing
Sranan Gold Announces Participation in Upcoming Capital Event Muskoka Conference and Munich Mining Conference
Sranan Gold Corp. (CSE: SRAN) (FSE: P84) (Tradegate: P84) (‘Sranan’ or the ‘Company’) announces that CEO Oscar Louzada will be participating in the following investor conferences: Capital Event MuskokaDate: September 26-28,…
-
-
Investing
Blue Lagoon Announces Commissioning of MBBR Water Treatment System and Start of Underground Operations at Dome Mountain
(TheNewswire) September 15, 2025 TheNewswire – Vancouver, British Columbia Blue Lagoon Resources Inc. (‘Blue Lagoon’ or the ‘Company’) (CSE: BLLG,OTC:BLAGF; OTCQB: BLAGF; FSE: 7BL) is pleased to announce that the…
-
Here’s a quick recap of the crypto landscape for Monday (September 15) as of 9:00 a.m. UTC. Get the latest insights on Bitcoin, Ethereum and altcoins, along with a round-up…
-
Fast-food restaurants are losing breakfast customers to convenience stores. Morning meal traffic to fast-food chains rose 1% in the three months ended in July, while visits to food-forward convenience stores…
-
Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026…